We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
This document contains a synopsis of causation occurring in Osteoporosis.
A preventative service encouraging people at risk of osteoporotic fractures to remain physically active and learn to self-manage their condition.
Farm Animal Welfare Council advice to government about the extent of hens' bone fractures in all production systems and the impact on welfare.
Calcitonin-containing medicines should no longer be used in treatment of osteoporosis.
Atypical femoral fractures reported rarely with bisphosphonate therapy, mainly in patients receiving long-term treatment for osteoporosis.…
Data suggests that long-term use of carbamazepine, phenytoin, primidone, and sodium valproate is associated with decreased bone mineral density that may lead to osteopenia, osteoporosis, and increased fractures.
Volume 16 of the non-technical summaries granted under the Animals (Scientific Procedures) Act 1986 during 2013.
…Denosumab 60mg (Prolia) is authorised for use in adults with osteoporosis and other bone loss conditions – it should not be used in children and adolescents younger than 18 years.
Advice and guidance on the health needs of migrant patients for healthcare practitioners.
Evaluate a patient’s individual factors for benefits and risks before initiating treatment with denosumab 60mg, particularly in those with previous vertebral fracture. Patients should not stop denosumab without specialist re…
Restricted indication and new monitoring requirements.
Studies of cardiovascular risk don’t support prescribing changes.
Volume 2 of the non-technical summaries granted under the Animals (Scientific Procedures) Act 1986 during 2013.
First published during the 2010 to 2015 Conservative and Liberal Democrat coalition government
Projects granted during 2015 that have a primary purpose of basic research: musculoskeletal system.
Minimising the risk of osteonecrosis of the jaw; monitoring for hypocalcaemia.
Update of data on musculoskeletal conditions and services for local populations in England.
Denosumab is associated with a risk of osteonecrosis of the jaw, osteonecrosis of the external auditory canal has also been reported with denosumab.
Evidence and guidance for healthcare professionals to assess risks, advise patients and families and prevent falls and fractures.
Recent epidemiological evidence of an increased risk of fracture with long-term use of proton pump inhibitors (PPIs).
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).